LOGIC-insulin - Clinical validation and filing for regulatory approval of a blood glucose regulator for the Intensive Care Unit
From 01-01-2011 to 31-12-2012
Description
Critically ill
patients, admitted to the Intensive Care Unit after e.g.
major trauma,cardiac surgery, transplantation or severe infections are in an
imminent life-threatening condition. Criticalillness typically leads to an
increase of the blood glucose concentrations: the so-called stresshyperglycaemia. While stress hyperglycaemia has traditionally been regarded as an
adaptive, beneficialresponse, it has also been clear from observational studies
that hyperglycaemia, as well ashypoglycaemia, are associated with increased
risk of death in critically ill patients. The associationbetween blood glucose
levels and mortality risk follows a J-curved relationship with the nadir
roughlybetween 80-140 mg/dL . The first randomized controlled trial (RCT)
that showed hyperglycaemiaactively contributes to worsened patient outcome was
performed in Leuven. This study targeted a “strictlynormal level for fasting
blood glucose”, i.e. 80-110 mg/dL versus treating hyperglycaemia only when itexceeded
the renal threshold of 215 mg/dL. The insulin dose-adaptations were based on a
guideline tostimulate intuitive and anticipating decision making by bedside
nurses. At the same time the study wasset up with a single-centre,
proof-of-concept design. The latter encompassed precise arterial bloodglucose
measurements with a blood gas analyser and the administration of insulin via an
accuratesyringe pump and a homogeneous patient population (mainly cardiac
surgery and high risk/complicatednon-cardiac surgery). The study showed
that maintaining strict normoglycaemia by “intensive insulintherapy” lowered
ICU mortality from 8.0% to 4.6%and in-hospital mortality from 10.9% to 7.2%.Further,
ICU morbidity was reduced by preventingorgan failure (reflected in a shorter
duration ofmechanical ventilation, a decreased incidence ofacute kidney
failure, severe infections andpolyneuropathy and less blood transfusions).Generalising
to the medical and paediatric critically illpatient population, these results
were confirmed inthe same context of a well controlled, single-centreexpert
setting.
Team
- Greta Van den Berghe, Co-promoter (External)
- Bart De Moor, Co-promoter
- Dieter Mesotten, Promoter (External)
- Tom Van Herpe, Team member
Financing
Funding: KU Leuven - Internal Funding KU Leuven
Program/Grant Type: IOF - IOF-mandaten: Postdoctoral Fellowships
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.